iRhythm Technologies (Nasdaq:IRTC) announced today that it appointed a new chief financial officer and a new chief human resources officer. The San Francisco-based wearable electrocardiogram monitors developer will bring in Brice Bobzien as CFO and Reyna Fernandez as EVP and chief human resources officer (CHRO). Fernandez’s appointment was made effective today, while Bobzien will join […]
iRhythm Technologies
FDA clears iRhythm’s ZEUS system for Zio Watch
iRhythm Technologies (Nasdaq:IRTC) announced today that it received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) system. ZEUS, produced in partnership with Google’s life sciences sister company Verily, combines deep-learned algorithms with iRhythm’s cardiac arrhythmia service, providing the AI algorithm component for the Zio Watch sensor-based wearable for non-invasive, clinical-grade, long-term continuous monitoring […]
iRhythm brings another Dexcom veteran into its C-suite
iRhythm Technologies (Nasdaq:IRTC) announced today that it appointed Chad Patterson as its next chief commercial officer. Patterson will join the wearable electrocardiogram monitors developer’s executive leadership team and, as CCO, he will oversee the company’s commercial strategy, operations and execution. He most recently served as chief marketing officer at Dexcom. He will make the move […]
iRhythm stock up on positive news out of CMS
iRhythm Technologies (Nasdaq:IRTC) stock soared today on positive reimbursement news out of CMS as the agency makes 2023 fee schedule proposals. Truist analysts yesterday evening pointed to CMS proposing a national coverage determination (NCD) of $229 for the ZioXT wearable cardiac monitor. When incorporating the geographic physician payment adjustments, the analysts thought the actual payment […]
iRhythm stays silent on federal grand jury subpoenas
More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a […]
iRhythm stock soars on Street-beating Q1; C-Suite changes continue
iRhythm Technologies (Nasdaq:IRTC) posted first-quarter results that beat the consensus forecast on Wall Street and increased its outlook for the rest of the year, sending the stock up more than 10% by this morning. The San Francisco-based developer of remote external electrocardiogram monitors reported a net loss of $50.6 million, or -$1.71 per share, on […]
iRhythm brings Stanford professor into C-suite
iRhythm Technologies (Nasdaq:IRTC) this week announced it appointed Dr. Mintu Turakhia as chief medical officer and chief scientific officer. Turakhia is a professor of medicine at the Stanford University School of Medicine and the director and co-founder of the Stanford Center for Digital Health. He is also a cardiac electrophysiologist with more than 20 years […]
Studies show that iRhythm’s Zio detects AFib early, prevents hospital admissions
iRhythm Technologies (Nasdaq:IRTC) announced results of multiple studies supporting the use of its Zio technology in detecting AFib. San Francisco-based iRhythm presented the results of three clinical research studies at The American College of Cardiology’s 71st Annual Scientific Session & Expo. According to a news release, the studies further validate Zio as an option for […]
Former CEO Kevin King to retire from iRhythm’s board of directors
iRhythm Technologies (Nasdaq:IRTC) announced today that Kevin King will retire from the company’s board of directors. King joined San Francisco–based iRhythm’s board in July 2012 and served as the company’s president and CEO from then until January 2021. “On behalf of the entire iRhythm team, I would like to thank Kevin for his contributions over […]
New research backs iRhythm’s Zio XT against Holter, event monitors
iRhythm Technologies (NSDQ:IRTC) announced today that a study demonstrated the superiority of its Zio XT compared to other cardiac monitors. San Francisco-based iRhythm’s KP-Rhythm2 study — published in the American Journal of Cardiology — examined the efficiency of Zio XT, Holter monitors and event monitors with the aim of assessing diagnostic yield, outcomes and resource utilization by monitoring […]
iRhythm’s fourth-quarter beats the Street as a new leader joins the ranks
iRhythm Technologies (NSDQ:IRTC) posted fourth-quarter results today that beat the consensus forecast on Wall Street while naming the high-level hire the CEO wanted to make when he last spoke with Medical Design & Outsourcing. The San Francisco-based developer of remote external electrocardiogram monitors reported a net loss of $32.5 million, or $1.10 per share, on […]